“…Because of these prosocial effects, the oxytocinergic system has emerged as a leading target for the development of novel pharmacotherapies for treating social impairments, like those seen in autism spectrum disorders (ASD; Guastella and MacLeod, 2012;Modi and Young, 2012). Although nonapeptides, like OT and vasopression, are large molecular weight compounds that do not readily cross the blood brain barrier when given peripherally, several studies have now confirmed the effectiveness of an intranasal (IN) administration route for delivering these compounds to the central nervous system (CNS) in humans and animals (Born et al, 2002;Chang et al, 2012;Neumann et al, 2013;Striepens et al, 2013;Modi et al, 2014). Using this method, studies have reported broad effects of OT on the perception of social stimuli including increasing the salience of the eyes in faces (Guastella et al, 2008;Andari et al, 2010), altering the perception of facial expressions (Domes et al, 2007a,b;Fischer-Shofty et al, 2010;Gamer et al, 2010;Parr et al, 2013), enhancing memory for face identity (Savaskan et al, 2008;Rimmele et al, 2009), and decreasing social vigilance (Ebitz et al, 2013).…”